Mild-to-moderate renal impairment is associated with platelet activation: A cross-sectional study

Clinical Nephrology

Volumn 70, Issue 4, 2008, Pages 325-331

  Thijs, A ^a,d   Nanayakkara, P W B ^a,d   ter Wee, P M ^a   Huijgens, P C ^a   van Guldener, C ^b   Stehouwer, C D A ^c,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherothrombosis; Blood platelets; Mild to moderate renal impairment; Platelet activation

Indexed keywords

ACTIVATED FIBRINOGEN RECEPTOR; CD63 ANTIGEN; CREATININE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB ALPHA; PADGEM PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE;

ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIOXIDANTS; BIOLOGICAL MARKERS; CREATININE; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; P-SELECTIN; PLACEBOS; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEIN IIB; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, FIBRINOGEN; RISK FACTORS;

EID: 54949118676     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991; 65: 467-473.
2. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991; 11: 1223-1230.
3. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86.
4. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Serum Thromb Hemost. 2004; 30: 579-589.
5. Boos CJ, Lip GY. Platelet activation and cardiovascular outcomes in acute coronary syndromes. J Thromb Haemost. 2006; 4: 2542-2543.
6. Cetin O, Bekpinar S, Unlucerci Y, Turkmen A, Bayram C, Ulutin T. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation. Clin Nephrol. 2006; 62: 97-102
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
8. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006; 114: 2871-2891.
9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
10. Go AS, Chertow GM, Fan A McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
11. Gorog P, Kovacs IB. Lipid peroxidation by activated platelets: a possible link between thrombosis and atherogenesis. Atherosclerosis. 1995; 115: 121-128.
12. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002; 62: 1402-1407.
13. Horstrup K, Jablonka B, Honig-Liedl P, Just M, Kochsick K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994; 225: 21-27.
14. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006; 19: 317-322.
15. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004; 43: 244-253.
16. Levey AS, Bosch JP, Lewis dB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461-470.
17. Massherg S, Brand K, Gruner S, Page S, Muller E, Muller I et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196: 887-896.
18. Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP. Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood. 2007; 109: 566-576.
19. Michelson AD, Shattil SJ. The use of flow cytometry to study platelet activation. In: Watson SP, Authi KS (eds). Platelets, a practical approach. Oxford: IRL Press; 1996. p. 111.
20. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745-753.
21. Nanayakkara PWB, Guldener van C, Wee ter PM, Scheffer PG, Ittersum van FJ, Twisk JW, Teerlink T, Dorp van W, Stehouwer CDA. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine-lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease. Results from the Anti-Oxidant Therapy in Chronic renal insufficiency (ATIC) Study. Arch Intern Med. 2007; 167: 1262-1270.
22. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest. 1995; 96: 1564-1572.
23. Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow-cytometric characterisation of platelet function. Thromb Haemost. 1998; 79: 885-896.
24. Theilmeier G, Lenaerts T Remacle C, Collen D, Vermylen J, Hoylaerts MF. Circulating activated platelets assist THP-1 monocytoid/ endothelial cell interaction under shear stress. Blood. 1999; 94: 2725-2734.
25. 1 on platelets. Blood. 2007; 109: 595-602.
26. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000; 15: 454-457.